Skip to main content
. Author manuscript; available in PMC: 2011 Oct 20.
Published in final edited form as: Bioconjug Chem. 2010 Oct 20;21(10):1753–1761. doi: 10.1021/bc900522x

Figure 6.

Figure 6

a) Transfection efficiency of p(TETA/CBA)5k,10/90, 50/50 and 0/100% p(TETA/CBA)5k/p(TETA/CBA)5k-g-PEG2kpolyplex formulations with CMVLuc in the presence and absence of serum. The 10 and 50% PEG formulations are significantly better gene carriers than bPEI 25kDa and p(TETA/CBA) in the presence of serum. However these two formulations are not significantly different from each other. b) Cell viability with analogous polyplex formulations in serum-containing media (p < 0.05, n=6).